Onxeo will publish its full-year results on April 14, 2023
The annual general meeting will be held on June 6, 2023
Paris (France), March 14, 2023 – 6:00 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced new dates for the publication of its 2022 full-year results and the holding of its annual general meeting.
The Company's Board of Directors decided to schedule the publication of the 2022 full-year results on April 14, 2023, after market close, and the holding of its annual general meeting on June 6, 2023. The date for the publication of the 2023 half-year results, scheduled for September 28 after market close, remains unchanged.